FY2025 EPS Estimate for Prenetics Global Boosted by Analyst

Prenetics Global Limited (NASDAQ:PRE) – Investment analysts at Cantor Fitzgerald upped their FY2025 earnings per share estimates for shares of Prenetics Global in a report released on Thursday, November 13th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will post earnings of ($2.22) per share for the year, up from their previous estimate of ($2.61). Cantor Fitzgerald currently has a “Overweight” rating and a $32.00 price target on the stock. The consensus estimate for Prenetics Global’s current full-year earnings is ($3.30) per share. Cantor Fitzgerald also issued estimates for Prenetics Global’s FY2026 earnings at $1.52 EPS.

Prenetics Global (NASDAQ:PRE) last released its earnings results on Monday, November 10th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.14. The firm had revenue of $23.56 million for the quarter, compared to analyst estimates of $26.00 million. Prenetics Global had a negative return on equity of 30.12% and a negative net margin of 60.70%. Prenetics Global has set its FY 2025 guidance at EPS.

PRE has been the subject of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Prenetics Global from a “hold” rating to a “buy” rating in a research report on Saturday. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $32.00.

Prenetics Global Trading Down 3.4%

PRE opened at $11.79 on Monday. The business has a 50 day moving average of $13.25 and a 200-day moving average of $9.75. The stock has a market capitalization of $198.43 million, a price-to-earnings ratio of -4.79 and a beta of 0.35. Prenetics Global has a 1-year low of $3.09 and a 1-year high of $17.99.

Institutional Investors Weigh In On Prenetics Global

Institutional investors and hedge funds have recently bought and sold shares of the business. Nomura Holdings Inc. lifted its holdings in shares of Prenetics Global by 3.3% during the 1st quarter. Nomura Holdings Inc. now owns 333,528 shares of the company’s stock worth $1,307,000 after acquiring an additional 10,576 shares during the period. UBS Group AG increased its stake in Prenetics Global by 581.9% in the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after acquiring an additional 39,733 shares during the period. JPMorgan Chase & Co. acquired a new position in Prenetics Global in the third quarter worth about $65,000. Aberdeen Group plc acquired a new position in Prenetics Global in the third quarter worth about $979,000. Finally, Stevens Capital Partners bought a new position in Prenetics Global during the second quarter worth about $137,000. Institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.